Adverse reactions associated with systemic polymyxin therapy

Pharmacotherapy

Volumn 35, Issue 1, 2015, Pages 28-33

  Justo, Julie Ann ^a   Bosso, John A ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Colistin; Polymyxin; Polymyxin B; Toxicity

Indexed keywords

ASCORBIC ACID; COLISTIMETHATE; COLISTIN; MEGALIN; POLYMYXIN; POLYMYXIN B; POLYMYXIN DERIVATIVE; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ALLERGIC REACTION; ANTIOXIDANT ACTIVITY; APNEA; ARTICLE; ATAXIA; BACTERIAL INFECTION; CONFUSION; DIZZINESS; DRUG EXPOSURE; DRUG INFORMATION; DRUG MONITORING; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; MONOTHERAPY; MYOPATHY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PSYCHOSIS; RESPIRATORY ARREST; RESPIRATORY DISTRESS; RISK ASSESSMENT; RISK REDUCTION; SEIZURE; TREATMENT DURATION; DOSE RESPONSE; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; KIDNEY; NERVOUS SYSTEM; RISK FACTOR;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; KIDNEY; NERVOUS SYSTEM; POLYMYXINS; RISK FACTORS;

EID: 84926176665     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1493     Document Type: Article

References (40)

1. Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin patients with renal disease. N Engl J Med 1962;266:759-62.
2. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68.
3. Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 2013;57:6319-24.
4. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 2012;56:4625-9.
5. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011;55:4044-9.
6. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 2012;67:452-9.
7. Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014;58:2740-6.
8. Keirstead ND, Wagoner MP, Bentley P, et al. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol Sci 2014;137:278-91.
9. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12.
10. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013;57:1300-3.
11. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014;43:349-52.
12. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011;53:879-84.
13. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94.
14. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012;65:80-7.
15. Kwon J-A, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010;35:473-7.
16. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503-5.
17. Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy 2013;33:812-6.
18. Oliveira MS, Prado GVB, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 2009;65:431-4.
19. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010;65:2231-7.
20. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extendedinterval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study Clin Infect Dis 2012;54:1720-6.
21. Ko Hj, Jeon Mh, Choo Ej, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011;117:c284-8.
22. Nord NM, Hoeprich PD. Polymyxin B and colistin: a critical comparison. N Engl J Med 1964;270:1030-5.
23. Nation RL, Velkov T, Li J. Colistin and polymyxin B: are they like peas in a pod or chalk and cheese? Clin Infect Dis 2014;59:88-94.
24. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013 May;22:524-31.
25. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005;26:504-7.
26. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27.
27. Mostardeiro MM, Pereira CAP, Marra AR, Pestana JOM, Camargo LFA. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother 2013;57:1442-6.
28. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005;5:1-8.
29. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012;56:2392-6.
30. Sandri AM, Landersdorfer CB, Jacob J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 2013;68:674-7.
31. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP 1991;25:1168-70.
32. Fernández AB, Pérez M, Soto L. Sudden respiratory muscle paralysis and apnea in a patient infected with multidrug-resistant Pseudomonas aeruginosa treated with intravenous colistin. Int J Infect Dis 2013;17:e357.
33. Wahby K, Chopra T, Chandrasekar P. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis 2010;50:e38-40.
34. Wunsch H, Moitra VK, Patel M, Dzierba AL. Polymyxin use associated with respiratory arrest. Chest 2012;141:515-7.
35. Spapen HD, Honore PM, Gregoire N, et al. Convulsions and apnoea in a patient infected with New Delhi metallo-β-lactamase-1 Escherichia coli treated with colistin. J Infect 2011;63:468-70.
36. Decker DA, Fincham RW. Respiratory arrest in myasthenia gravis with colistimethate therapy. Arch Neurol 1971;25:141-4.
37. Vaara M. Novel derivatives of polymyxins. J Antimicrob Chemother 2013;68:1213-9.
38. Brandenburg KS, Rubinstein I, Sadikot RT, Önyüksel H. Polymyxin B self-associated with phospholipid nanomicelles. Pharm Dev Technol 2012;17:654-60.
39. Bode-Böger SM, Schopp B, Tröger U, Martens-Lobenhoffer J, Kalousis K, Mailänder P. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. Int J Antimicrob Agents 2013;42:357-60.
40. Pai MP. Polymyxin B dosing in obese and underweight adults. Clin Infect Dis 2013;57:1785.